Corporate Management


Emmanuel Dulac

President and Chief Executive Officer

Emmanuel holds a Doctorate in Pharmacology (PharmD, Ph.D.) from the University of Paris XI. He has also completed an MBA at the ESSEC School in Paris.

Prior to joining Zealand, Emmanuel was Chief Commercial Officer for Alnylam Pharmaceuticals, a biopharmaceutical company based in Boston, where he was responsible for establishing country operations and building commercial capabilities to successfully launch their first commercial drug.

Emmanuel is an accomplished leader with 25 years of experience in the pharmaceutical industry, building upon earlier roles at Novartis, Abbott, and Sanofi. He recently joined the board of directors at Proteostasis Therapeutics, Inc.


Adam Steensberg

Executive Vice President, Chief Medical and Development Officer

Adam is a certified medical doctor and holds a
Doctor of Medical Sciences degree (D.M.Sc./ from the University of Copenhagen, Denmark, and an MBA from IMD, Switzerland. Adam has published more than 45 peer-reviewed scientific papers in renowned international journals.

Prior to joining Zealand, Adam led clinical research teams as medical director at Novo Nordisk and worked as a clinician at Rigshospitalet, University of Copenhagen. Adam was a medical and scientific advisor in the areas of endocrinology, cardiology, gastroenterology and rheumatology, and has significant experience of leading regulatory strategies.

Adam is a board member of Beta Bionics, Inc.


Andrew Parker

Executive Vice President and Chief Science Officer

Andrew holds a Ph.D. from the National Institute for Medical Research in Mill Hill, London, UK. He conducted postdoctoral research at Johns Hopkins School of Medicine, Baltimore, U.S., and also has an MBA from the University of Warwick Business School, UK. Andrew has published more than 25 peer-reviewed scientific papers in renowned international journals.

Prior to joining Zealand, Andrew was general partner and Scientific director of Eclosion2 & Cie SCPC in Switzerland. CEO of Arisgen SA, an Eclosion2 portfolio company developing an oral peptide drug delivery technology.

Andrew has more than 20 years’ experience in international pharmaceutical, biotech and start-up companies, including several years at Shire Pharmaceuticals, Opsona Therapeutics and AstraZeneca.


Ivan Møller

Senior Vice President, Technical Development and Operations

Ivan holds a Master of Science in Chemical Engineering from the Technical University of Denmark (DTU) and a Master of Business Administration from Harvard Business School.

Prior to joining Zealand, Ivan worked for Novartis in both generics and pharmaceutical manufacturing, as well as in strategy, quality assurance, contract manufacturing and supply chain leadership in Germany, the U.S. and Switzerland.

Ivan was project leader at The Boston Consulting Group in the pharmaceutical R&D and manufacturing areas.


Marino Garcia

Senior Vice President, Corporate and Business Development

Marino holds a Bachelorís Degree in Business Administration from Concordia University in Montreal, Quebec, and an MBA from the Richard Ivey School of Business at Western University in London, Ontario.

Marino has almost 25 years of global pharma and biotech experience in senior commercial, corporate strategy, and business development roles. He has held various U.S. and international leadership positions of increasing responsibility at pharmaceutical companies, including Synergy Pharma, Aptalis Pharma, Vifor Pharma, Aspreva Pharmaceuticals, Pfizer and Eli Lilly & Co.